Monitoring clozapine: Are fingerprick blood and plasma clozapine levels equivalent to arm venipuncture blood and plasma levels?

Therapeutic Drug Monitoring

Volumn 25, Issue 4, 2003, Pages 469-472

  Goossen, Randolph B ^a,b   Freeman, David J ^a   Satchell, Anne Marie ^a   Urquhart, Bradley L ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b PsycHealth Centre   (Canada)

Author keywords

Clozapine; Fingerprick; Plasma

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4;

ACCURACY; ADULT; ARM BLOOD VESSEL; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; EVALUATION; FEMALE; FINGER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MENTAL DISEASE; OUTPATIENT; PILOT STUDY; PRICK TEST; PRIORITY JOURNAL; RELIABILITY; SOLID PHASE EXTRACTION; STEADY STATE; TECHNIQUE; VEIN PUNCTURE;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BLOOD SPECIMEN COLLECTION; CLOZAPINE; DRUG MONITORING; FEMALE; FINGERS; HUMANS; MALE; MIDDLE AGED; PHLEBOTOMY; PILOT PROJECTS;

EID: 0043269276     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200308000-00009     Document Type: Article

References (14)

1. Kronig MH, Munne RA, Szymanski S, et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry. 1995;152:179-182.
2. Guille C, Sachs GS, Ghaemi SN. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2000;61:638-642.
3. Kaladjian A, Bery B, Deturmeny E, et al. Clozapine monitoring: plasma or serum levels? Ther Drug Monit. 1999;21:327-329.
4. Young CR, Bowers MB Jr, Mazure CM. Management of the adverse effects of clozapine. Schizophrenia Bull. 1998;24:381-390.
5. Freeman DJ, Oyewumi LK. Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin Pharmacokinet. 1997;32:93-100.
6. Oloesen OV, Linnett K, Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharm. 2001;41:823-832.
7. Chang WH, Augustin B, Lane HY, et al. In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine. Psychopharmacology (Berl). 1999;145:191-198.
8. Silver H. Fluvoxamine as an adjunctive in the treatment of schizophrenia. CNS Drug Rev. 2001;7:283-304.
9. Haring C, Meise U, Humpel C, et al. Dose-related plasma levels of clozapine: influence of smoking behavior, sex and age. Psychopharmacology (Berl). 1989;99(Suppl):S38-S40.
10. Seppala NH, Leinonen EVJ, Lehtonen M-L, et al. Clozapine serum concentrations are lower in smoking than non-smoking schizophrenic patients. Pharmacol Toxicol. 1999;85:244-246.
11. Ozdemir V, Kalow W, Okey AB, et al. Treatment-resistance to clozapine in association with ultrarapid CYPIA2 activity and the C↑A polymorphism in intron 1 of the CYPIA2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol. 2001;21:603-607.
12. Tschen AC, Rieder MJ, Oyewmui LK, et al. The cytoxicity of clozapine metabolites: implications for predicting clozapine-induced agranulocytosis. Clin Pharmacol Ther. 1999;65:526-532.
13. Torrey EF. The inner world of madness. In: Torrey EF. ed. Surviving Schizophrenia: A Manual for Families, Consumers, and Providers, 4th ed, New York: HarperCollins, 2001:41.
14. Freeman DJ, Li MC, Oyewumi K. Solid-phase extraction and high-performance liquid chromatographic analysis of clozapine and norclozapine in human plasma. Ther Drug Monit. 1996;18:688-692.